Du är här


Senzime: Meet Senzime at Euroanesthesia 2017

Uppsala, May 24, 2017. Senzime AB (publ) will be participating at
Euroanaesthesia 2017 in Geneva, Switzerland June 3-5, 2017.

Euroanaesthesia is Europe's largest annual event showcasing the latest
and the most relevant knowledge with medical experts active in the
field of anaesthesia, perioperative medicine, intensive care,
emergency medicine and pain treatment.

This international event gathers thousands of delegates and exhibitors
from over 80 countries. Upwards of 6000 delegates are expected from
all over the world.

Senzime is exhibiting at the meeting, please visit us at our booth #17

For further information, please contact:

Lena Söderström, CEO at Senzime AB

Tel: +46 708-16 39 12, email: lena.soderstrom@senzime.com


About Senzime

Senzime develops unique patient-oriented monitoring systems that make
it possible to assess patients' biochemical and physiological
processes before, during and after surgery. The portfolio of
technologies includes bedside systems that enable automated and
continuous monitoring of life-critical substances such as glucose and
lactate in both blood and tissues, as well as systems to monitor
patients' neuromuscular function perioperatively and in the intensive
care medicine setting. The solutions are designed to ensure maximum
patient benefit, reduce complications associated with surgery and
anesthesia, and decrease health care costs. Senzime operates in
growing markets that in Europe and the United States are valued in
excess of SEK 10 billion. The company's shares are listed on Nasdaq
First North (ticker SEZI). FNCA is Certified Adviser for Senzime.


Författare Cision

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.